Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Research Alliance Corp III (RACC)

Research Alliance Corp III agrees to merge with Oak Hill Bio, a rare disease biotech

Neutral Impact 4 of 5 m&a Written later

SPAC Research Alliance Corporation III (RACC) signed a business combination agreement on July 26, 2026 to acquire 100% of OHB Pediatrics Ltd., doing business as Oak Hill Bio, in exchange for newly issued RACC common stock. The combined company would be renamed Oak Hill Bio, Inc. and trade on Nasdaq as OAKH, with closing expected by year-end 2026 subject to shareholder approval and other conditions.

Key points

  • Base equity value of $160 million, plus a SAFE amount, divided by $10.00 per share sets the share count issued to Oak Hill Bio shareholders
  • Expected gross proceeds of about $175 million, including $75 million from RACC's trust account backstopped by RA Capital and a $100 million private financing
  • RACC shareholders may redeem Class A shares for cash from the trust account in connection with the transaction
  • Either party may terminate if the deal is not closed within six months of the agreement date, subject to extension provisions

The filing

CompanyResearch Alliance Corp III (RACC)
Form8-K, current report
Filed with the SECJul 27, 2026, 8:18 AM ET
Accession number0001193125-26-316954

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.